"So it could potentially be really, really appealing for the treatment of MASH [a chronic liver disease], for example." While it's still uncertain whether final retatrutide trial results will be available to submit to the FDA in 2025, Jonsson said it "might" happen, setting up the drug to potentially become available in 2026
The peptides used to produce these effects are novel structures that are not used medically
See the full semaglutide dosage chart for the complete schedule
its about formulations people can trust and use daily
The study used data on more than 145,000 people treated with GLP-1 agonists, and almost 292,000 people treated with DPP4 inhibitors.The researchers followed up participants after a mean of 3.9 years for the GLP-1 group and 5.4 years for the DPP4 group
Roll gently for 30-60 seconds